¸Þµð¾÷

´ëÇк´¿ø Çѹ溴¿ø
Á¾ÇÕº´¿ø ³ëÀκ´¿ø
°Ô½ÃÆÇ
°Ç°­Á¤º¸
º´¿ø¾à±¹Á¤º¸
Èú¸µ½ºÅ丮
Áúº´Á¤º¸
ÀǾàÇ°Á¤º¸
ÀÇÇм­Àû
ÀÓ´ëºÐ¾ç¸Å¸Å
¿¬¼ö°­ÁÂ
±³À°Á¤º¸
¸ÞµðÅå
´ëÇк´¿ø Á¾ÇÕº´¿ø Çѹ溴¿ø Ä¡°úº´¿ø ÇÑÀÇ¿ø ³ëÀÎÀü¹®º´¿ø º¸°Ç¼Ò
¼­¿ï ºÎ»ê ÀÎõ ´ë±¸ ´ëÀü ±¤ÁÖ ¿ï»ê °æ±â °­¿ø ÃæºÏ Ãæ³² °æºÏ °æ³² ÀüºÏ Àü³² Á¦ÁÖ ¼¼Á¾
Ä¡°ú ¾È°ú ÇǺΰú ¼ºÇü¿Ü°ú »êºÎÀΰú ºñ´¢±â°ú ¿Ü°ú ³»°ú Á¤Çü¿Ü°ú À̺ñÀÎÈÄ°ú ¼Ò¾Æ°ú ¾à±¹

¸ñ·Ï ¼öÁ¤ »èÁ¦

´ëÇѳ»ºÐºñÇÐȸ (¿Â¶óÀÎ) 2021³â Postgraduate Course : 2021-09-25

ÃßõÇϱâ
¿¬¼ö°­Á À̹øÁÖ BEST
 
´ëÇѳ»ºÐºñÇÐȸ (¿Â¶óÀÎ) 2021³â Postgraduate Course : 2021-09-25
±³À°ÀÏÀÚ : 2021-09-25
±³À°Àå¼Ò : ¿Â¶óÀÎ ±³À°  
±³À°ÁÖÁ¦ : (¿Â¶óÀÎ) 2021³â Postgraduate Course
ÁÖÃÖ±â°ü : ´ëÇѳ»ºÐºñÇÐȸ
´ã´çÀÚ : È«Áö¼ö
¿¬¶ôó : 02-2038-3771  
À̸ÞÀÏ : endo@endocrinology.or.kr      
±³À°Á¾·ù : ³»°ú      
Âü¼®¿¹»óÀοø : 200¸í
Èñ¸ÁÆòÁ¡ : 6Á¡  
Áö¿ª : ¼­¿ïƯº°½Ã
±³À°½Ã°£ : 6 ½Ã°£ 40ºÐ  
¼¼ºÎ¼ö°­·á : 70,000¿ø      
ºñ°í ºÀÁ÷ÀÇ/°³¿øÀÇ 5¸¸¿ø (ºñȸ¿ø 7¸¸¿ø)Àü°øÀÇ ¹× ±âŸ(±âÃÊÀÇÇÐÀÚ/°£È£»ç/¾à»ç µî) 3¸¸¿ø(ºñȸ¿ø 5¸¸¿ø)      

±¸ºÐ ¿ùÀÏ °­ÀǽǠ½Ã°£ ±³À°Á¦¸ñ  °­»ç¸í(¼Ò¼Ó) Çʼö°ú¸ñ
±³À°½Ã°£ 09-25  09:00~09:25 Áú·®ºÐ¼®¹ý ±âÃÊ À̷Р ¿ÀÇѺó(¼­°­´ë) 
±³À°½Ã°£ 09-25  09:25~09:50 ÀÓ»ó½Ã·á ¹Ì·®ºÐ¼®À» À§ÇÑ ½Ã·á °ü¸®  ÇÑ»ó¹ü(Áß¾Ó´ë) 
±³À°½Ã°£ 09-25  09:50~10:15 ÀÓ»ó½Ã·á ³» steroidogenesis Æò°¡ ±â¼ú  ÃÖ¸¸È£(KIST) 
±³À°½Ã°£ 09-25  10:15~10:40 ÀÓ»ó°Ë»ç½Ç¿¡¼­ÀÇ Áú·®ºÐ¼®¹ý µµÀÔ°ú ¿î¿µ  ¹ÚÇüµÎ(¼º±Õ°üÀÇ´ë) 
È޽Ġ09-25  10:40~10:50 Break  () 
±³À°½Ã°£ 09-25  10:50~11:15 Approach to the patient with an adrenal incidentaloma  ±èÈ¿Á¤(À»ÁöÀÇ´ë) 
±³À°½Ã°£ 09-25  11:15~11:40 New drugs for pitutiary diseases  ±¸Ã¶·æ(¿¬¼¼ÀÇ´ë) 
Åä·Ð 09-25  11:40~12:05 Q&A ¹× Panel Discussion  () 
½Ä»ç 09-25  12:05~12:45 Lunch Break  () 
±³À°½Ã°£ 09-25  12:45~13:10 Future game changer in diabetes (weekly basal insulin (icodec) and imeglimin)  È«ÁØÈ­(À»ÁöÀÇ´ë) 
±³À°½Ã°£ 09-25  13:10~13:35 SGLT2 inhibitor in chronic kidney disease, where is the lowest limit of eGFR?  ±è½Å°ï(°í·ÁÀÇ´ë) 
Åä·Ð 09-25  13:35~14:00 Q&A ¹× Panel Discussion  () 
È޽Ġ09-25  14:00~14:10 Break  () 
±³À°½Ã°£ 09-25  14:10~14:35 Best treatment option for RAI-refractory advanced thyroid cancer  Àü¹ÎÁö(¿ï»êÀÇ´ë) 
±³À°½Ã°£ 09-25  14:35~15:00 How to adopt the molecular testing in thyroid nodule diagnosis  Á¶¼±¿í(¼­¿ïÀÇ´ë) 
Åä·Ð 09-25  15:00~15:25 Q&A ¹× Panel Discussion  () 
È޽Ġ09-25  15:25~15:35 Break  () 
±³À°½Ã°£ 09-25  15:35~16:00 Mechanisms and therapeutic effects of osteoporosis medications  ¹é±âÇö(°¡Å縯ÀÇ´ë) 
±³À°½Ã°£ 09-25  16:00~16:25 Management strategies after discontinuation of denosumab  ±èºÎ°æ(°í½ÅÀÇ´ë) 
Åä·Ð 09-25  16:25~16:50 Q&A ¹× Panel Discussion  () 
ÆÄ¿ö¸µÅ© ±¤°íµî·Ï
ÀÌ °Ô½Ã¹°À» ÃßõÇÕ´Ï´Ù.
¸Þµð¾÷
" ´ëÇѳ»ºÐºñÇÐȸ (¿Â¶óÀÎ) 2021³â Postgraduate Course : 2021-09-25""ÀÇ ÀÌ¿ëÈı⳪ Ãßõ´ñ±ÛÀ» ³²°Ü À¯¿ëÇÑ Á¤º¸·Î °øÀ¯ÇսôÙ. ^^
¡å
ÀÌ °Ô½Ã¹°À» ÃßõÇÕ´Ï´Ù.
 
¸ñ·Ï ¼öÁ¤ »èÁ¦
ÀÌÀü±Û ÇѾç´ëÇб³º´¿ø (¿Â¶óÀÎ) APTS(Asia-Pacific Society of Thyroid Surgery) : 2021-09-25
´ÙÀ½±Û °­³²¼¼ºê¶õ½ºº´¿ø Á¦ 14ȸ Èñ±Í½Å°æ±ÙÀ°°èÁúȯ¡¤È£ÈíÀçÈ° ½ÉÆ÷Áö¾ö : 2021-09-25
¹øÈ£ Á¦¸ñ Ãßõ Á¶È¸ µî·ÏÀÏ
422 ¼­¿ï Á߾Ӵ뺴¿ø È£Èí±â¾Ë·¹¸£±â³»°ú ¿¬¼ö°­Á : 2018-09-09 1 804 2018-08-15
421 ¼­¿ï ´ëÇѼºÇü¿Ü°úÇÐȸ Ç׳ëÈ­¼ºÇü¿¬±¸È¸ Á¦4ȸ ½ÉÆ÷Áö¾ö : 2018-09-09 0 818 2018-08-15
420 ¼­¿ï ´ëÇѺñ¸¸ÇÐȸ Á¦1ȸ ºñ¸¸Àü¹®°¡ ½ÉÈ­°úÁ¤: ºñ¸¸ Àü¹® ÀÎÁ¤ÀÇ ±³À° Part 1. : 2018-09-09 0 582 2018-08-15
419 °æ±â ºÐ´ç¼­¿ï´ëÇб³º´¿ø 2018³â Çù·Âº´ÀÇ¿ø ÀÇ»ç ¿¬¼ö°­Á : 2018-09-09 0 1,365 2018-08-15
418 ¼­¿ï Á¦1ȸ ´ëÇѼÒÈ­±â³»½Ã°æÇÐȸ ESD¿¬±¸È¸ ½ÉÆ÷Áö¾ö : 2018-09-08 0 868 2018-08-15
417 ¼­¿ï Á¦11ȸ ¼º±Õ°üÀÇ´ë »ï¼º¼­¿ïº´¿ø ÁßȯÀÚÀÇÇÐ ¿¬¼ö°­Á Basic Concepts in Intensive Care, 2018 (BACIC 2018) : 2018-09-08 0 1,382 2018-08-15
416 ¼­¿ï ´ëÇÑÁ¤Çü¿Ü°úÇÐȸ °í·Á´ëÇб³ °í°üÀý ½ÉÆ÷Áö¿ò : 2018-09-08 0 1,107 2018-08-15
415 ¼­¿ï 2018 ´ëÇÑ¿ä·Î»ý½Ä±â°¨¿°ÇÐȸ ¿öÅ©¼¥ : 2018-09-08 0 519 2018-08-15
414 ºÎ»ê ´ëÇѼ¼Æ÷º´¸®ÇÐȸ International Session of the 30th Annual Fall Meeting of the Korean Society for Cytopathology : 2018-09-08 0 600 2018-08-15
413 ºÎ»ê 2018³â ºÎ¿ï°æ³»ºÐºñ´ë»çÇÐȸ ´ç´¢º´±³À°ÀÚ ¼¼¹Ì³ª : 2018-09-08 0 1,063 2018-08-15
412 ±¤ÁÖ Àü³²´ëº´¿ø Á¦ 3Â÷ Àü³²´ëÇб³ ÀÇ°ú´ëÇÐ ½Å°æ°úÇб³½Ç ¿¬¼ö°­Á : 2018-09-08 0 1,091 2018-08-15
411 ºÎ»ê ºÎ»ê´ëº´¿ø 2018³â Á¦1Â÷ ¸ð¹ß¿¬¼ö±³À° (ÁÖÁ¦: Å»¸ðÁõÀÇ Áø´Ü°ú Ä¡·á) : 2018-09-08 0 1,434 2018-08-15
410 °æ±â ¾ÆÁÖ´ëÇб³º´¿ø Á¦6ȸ ¾ÆÁÖ ´ç´¢¹ß ¹× â»ó ½ÉÆ÷Áö¾ö : 2018-09-08 0 1,214 2018-08-15
409 ±¤ÁÖ 2018 Àü³²´ëÇб³º´¿ø ÁßȯÀÚÀÇÇнÉÆ÷Áö¿ò ¹× ±â°èȯ±â¿öÅ©¼ó : 2018-09-08 0 739 2018-08-15
408 ¼­¿ï 2018 ´ëÇÑ¿ä·Î»ý½Ä±â°¨¿°ÇÐȸ ¿öÅ©¼¥ : 2018-09-07 0 467 2018-08-15
1381 | 1382 | 1383 | 1384 | 1385 | 1386 | 1387 | 1388 | 1389 | 1390
 
Ä¿¹Â´ÏƼ
°Ô½ÃÆÇ
°Ç°­Á¤º¸
º´¿ø¾à±¹
Èú¸µ½ºÅ丮
Áúº´Á¤º¸
ÀǾàÇ°Á¤º¸
ÀÇÇм­Àû
ÀÓ´ë¸Å¸Å
¿¬¼ö°­ÁÂ
±³À°Á¤º¸
º´¿øȨÆäÀÌÁö
¸ÞµðÅå
ÇÑÀÇ¿ø
¼ºÇü¿Ü°ú
Ä¡°ú
¾È°ú
¿©¼ºº´¿ø
³»°ú
Á¤Çü¿Ü°ú
ÇǺΰú
¼Ò¾Æ°ú
À̺ñÀÎÈÄ°ú
ºñ´¢ÀÇÇаú
¿ä¾çº´¿ø
ÀçÈ°ÀÇÇаú
µ¿¹°º´¿ø
±âŸº´ÀÇ¿ø
Ãë¾÷°ü·Ã
Áö¿ø¼­¾ç½Ä
¼­·ù¾ç½Ä
¸Þµð¾÷ ¸ð¹ÙÀÏÀ¥
¸Þµð¾÷